Core Viewpoint - Baiyang Pharmaceutical is making significant progress in the global launch and clinical application of the ZAP-X Mars surgical robot, establishing a comprehensive strategy in the precision radiotherapy sector [1] Group 1: Company Developments - From December 5 to 9, Baiyang Pharmaceutical achieved key milestones including the production launch of the global manufacturing base, initiation of clinical research, and establishment of radiotherapy centers [1] - The ZAP-X has received approval for market launch in 24 countries and regions worldwide, with over 5,000 clinical application cases reported [1] Group 2: Strategic Initiatives - Baiyang Pharmaceutical is focusing on a full-chain strategy that includes global technology introduction, Chinese manufacturing for global supply, innovative service in radiotherapy centers, and continuous clinical research validation [1] - The company has officially launched its high-end manufacturing industrialization base on December 6, which is expected to have an annual production capacity of 100 units, with approximately 80% of orders coming from overseas [1]
百洋医药大放疗战略进入规模化落地新阶段